Selective Serotonin Reuptake Inhibitors: Sexual Dysfunction
The question
To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 13 May 2025 to Question 50758 on Selective Serotonin Reuptake Inhibitors: Sexual Dysfunction, which regulatory options are under consideration; and what his planned timeframe is for the review.
Answered by Karin Smyth
Following the next meeting of the Expert Working group (EWG), the Medicines and Healthcare products Regulatory Agency (MHRA) will seek advice from the Commission on Human Medicines on the recommendations of the EWG, on a wide range of regulatory options for the communication of the risk of sexual dysfunction where symptoms continue after taking antidepressants.
Once the regulatory procedure is completed, a public assessment report will be published which will contain the evidence underpinning any regulatory action. The MHRA anticipates that regulatory action will be finalised in Autumn 2025.
Verbatim has judged this answer against the question that was actually asked — answered, partly answered, or evaded. Sign in to see the verdict →